Zoya Technologies LLC · Dubai, UAE
We are a deep tech company, founded in 2022. Our flagship products are Zoyel - a Physical AI Operating System for healthcare - and ZoyeMed Terminals - Physical AI clinical infrastructure: systems that sense, measure, validate, reason longitudinally, govern, and escalate to a human clinician. The architecture emerged from deploying in places where getting it wrong is measured in patients, not metrics.
Our Conviction
The structural failure of most clinical AI systems is not their model architecture. It is the quality of their inputs. Virtually every clinical AI platform operating today asks a model to reason about a patient it has never physically encountered - from text, codes, and self-report. From filters and approximations of what the body is actually doing.
We believe this is a category error. Ground truth is not a dataset. It is a measurement - taken from the body, at the point of care, in real time. Everything built on anything less is an approximation of an approximation.
ZoyeMed 3.0 is our answer to this problem: a physical AI clinical infrastructure that acquires objective physiological data across 120+ validated sensor modalities, validates input quality before inference, reasons longitudinally across the patient's full history, and escalates to a human clinician under a governed protocol. Built at the edge. Deployed institutionally.
Leadership
Dr. Sabahat S. Azim is a physician and former Indian Administrative Service officer who has spent twenty-five years at the intersection of clinical medicine, public administration, and technology. The combination is not incidental - it is the architecture of ZoyeMed itself. A clinician's understanding of what actually happens in a patient encounter. An administrator's understanding of what scales through institutional systems. An engineer's insistence that both must be true simultaneously.
In 2010, Dr. Azim founded Glocal Healthcare Systems in Bankura, West Bengal, with a conviction that evidence-based, protocol-driven medicine could be made accessible at population scale. Over the next twelve years, Glocal deployed clinical AI across public health systems in West Bengal, Bihar, Uttar Pradesh, Odisha, Rajasthan, and Madhya Pradesh - accumulating more than eight million patient episodes and developing, through iterative deployment, one of the most operationally tested clinical decision support systems in the world.
The hardest deployments taught the most. The Sundarbans - tidal rivers, island-scattered villages, populations a day's boat journey from a physician - forced the architecture to function where connectivity is intermittent, power is unreliable, and patient self-report is structurally unreliable. Nabarangpur. Rajasthan's rural districts. These were not pilot programmes. They were the curriculum.
In 2022, Dr. Azim established Zoya Technologies LLC in Dubai, re-engineering the architecture from the ground up for edge-first inference, longitudinal multimodal AI, FHIR R4 interoperability, and institutional deployment at global scale. ZoyeMed 3.0 is the result: a Class IIa regulated physical AI clinical infrastructure, currently deployed across Mexico, Colombia, and Malaysia.
Company History
The architectural decisions in ZoyeMed 3.0 are answers to questions that were asked, repeatedly, in places where getting it wrong was measured in patients - not quarterly metrics.
Dr. Azim establishes Glocal to deliver standardised, process-engineered primary care across rural India. First site: Sonamukhi, Bankura district, West Bengal. The founding conviction: clinical protocols can be systematised. Access can be engineered.
Bayesian semantic CDSS developed and deployed across the Glocal network. Cited in peer-reviewed Clinical Decision Support Systems literature as among the more operationally visible CDSS globally at the time. Network grows to 1,100+ hospital beds across four Indian states.
Deployment into one of the most infrastructure-constrained environments in South Asia: tidal rivers, island-scattered villages, populations a day's boat journey from a physician. The architecture learns to function without reliable connectivity, reliable power, or reliable patient self-report. These constraints become design principles.
~100 clinics under India's National Health Mission in Rajasthan. Odisha Digital Dispensary Project in Nabarangpur - one of India's most underdeveloped districts - with a State MoU for 102 dispensaries across 23 districts. ~500 dispensaries in Madhya Pradesh. Cumulative patient volume crosses 5 million episodes.
Pandemic-capable autonomous terminal with integrated disinfection protocol deployed across Indian states during COVID-19. In a single calendar year, five simultaneous international recognitions - the WEF/Schwab, UN Innovation, Bloomberg New Economy Gamechanger, Frost & Sullivan Telemedicine Company of the Year, and Express Health - independently validate operational and clinical credibility.
Complete re-engineering for edge-first inference, longitudinal multimodal AI, clinical decision support guardrails, and FHIR R4 interoperability output. PCT patent filed for the longitudinal multimodal model architecture. First 44 commercial ZoyeMed units delivered to institutional programmes in Mexico. Colombia deployment agreement signed. Malaysia entity and IP registration initiated with MDEC.
22,000+ consultations through end-March 2026. 18,224 documented in a published Post-Market Clinical Experience Report (March 2025 – February 2026). Más Salud programme launched with Grupo Salinas across Elektra retail locations in Mexico City. Multi-year deployment agreements active in Colombia. WHX Dubai 2026 unveiling. CE Electrical and NYCE Mexico certifications current.
Global Presence
ZoyeMed 3.0 is in active institutional deployment in Mexico and Colombia, with Malaysia infrastructure underway. The regulatory programme spans five jurisdictions.
How We Build
These are not values statements drafted for a website. They are the constraints that emerged from deploying clinical AI in places where the margin for error is a human outcome.
Recognition
In 2020, five of the world's most credible institutions independently recognised the clinical and operational impact of the ZoyeMed lineage - in the same calendar year.
Regulatory & IP
ZoyeMed 3.0 is a regulated medical device, not a wellness product. Regulatory classification is a design constraint that forces clinical quality at the input layer.
Get in Touch
For institutional deployments, government health programmes, investment discussions, or media briefings - our team responds within two business days.